Landmark analysis at 3 and 6 mo by evaluable cytogenetic and molecular response categories for cumulative probability of 3-y EFS, OS, and FFS in response to each TKI therapy
| Response . | IM400 . | IM800 . | Nilotinib . | Dasatinib . | Overall . |
|---|---|---|---|---|---|
| Cytogenetic | |||||
| 3 mo | |||||
| 0 | 92/100/76 | 97/97/85 | 97/99/87 | 99/98/95 | 97/98/87 |
| 35 < 0 | 88/91/67 | 89/96/67 | 92/100/92 | 91/100/81 | 89/96/70 |
| >35 | 83/83/71 | 83/100/44 | 67/100/33 | 75/100/50 | 81/92/51 |
| 6 mo | |||||
| 0 | 96/100/79 | 97/99/87 | 99/100/92 | 99/99/94 | 97/99/89 |
| 35 < 0 | 80/100/78 | 88/95/52 | NA/NA/NA | 75/100/75 | 84/98/69 |
| >35 | 73/64/45 | 83/86/14 | 67/100/33 | 100/100/50 | 77/75/35 |
| Molecular | |||||
| 3 mo | |||||
| ≤1 | NA/NA | 94/78 | 96/88 | 100/95 | 96/85 |
| >1-10 | NA/NA | 100/69 | 94/75 | 100/82 | 98/73 |
| >10 | NA/NA | 80/60 | 100/100 | 27/50 | 61/61 |
| 6 mo | |||||
| ≤1 | NA/NA | 96/85 | 99/92 | 100/96 | 97/89 |
| >1-10 | NA/NA | 79/47 | 100/100 | 42/60 | 76/56 |
| >10 | NA/NA | 100/50 | 67/33 | 100/50 | 88/49 |
| Response . | IM400 . | IM800 . | Nilotinib . | Dasatinib . | Overall . |
|---|---|---|---|---|---|
| Cytogenetic | |||||
| 3 mo | |||||
| 0 | 92/100/76 | 97/97/85 | 97/99/87 | 99/98/95 | 97/98/87 |
| 35 < 0 | 88/91/67 | 89/96/67 | 92/100/92 | 91/100/81 | 89/96/70 |
| >35 | 83/83/71 | 83/100/44 | 67/100/33 | 75/100/50 | 81/92/51 |
| 6 mo | |||||
| 0 | 96/100/79 | 97/99/87 | 99/100/92 | 99/99/94 | 97/99/89 |
| 35 < 0 | 80/100/78 | 88/95/52 | NA/NA/NA | 75/100/75 | 84/98/69 |
| >35 | 73/64/45 | 83/86/14 | 67/100/33 | 100/100/50 | 77/75/35 |
| Molecular | |||||
| 3 mo | |||||
| ≤1 | NA/NA | 94/78 | 96/88 | 100/95 | 96/85 |
| >1-10 | NA/NA | 100/69 | 94/75 | 100/82 | 98/73 |
| >10 | NA/NA | 80/60 | 100/100 | 27/50 | 61/61 |
| 6 mo | |||||
| ≤1 | NA/NA | 96/85 | 99/92 | 100/96 | 97/89 |
| >1-10 | NA/NA | 79/47 | 100/100 | 42/60 | 76/56 |
| >10 | NA/NA | 100/50 | 67/33 | 100/50 | 88/49 |
Patients with imatinib 400 were excluded from the molecular analyses at 3 and 6 mo due to low percentage of patients with available data.
NA, no data applicable.